Abstract:Purpose: To compare treatment outcomes and adverse events between concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) and conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil (CF-RT). Methods and Materials: We retrospectively investigated treatment outcomes and adverse events in 121 patients with advanced esophageal cancer who underwent concurrent chemoradiotherapy with CF-RT (n = 83) or DCF-RT (n = 38). In the CF-RT group, patients were administered cisplatin (70 mg/m2) and 5-fluorouracil (700 mg/m2) for 5 days; in the DCF-RT group, patients were administered docetaxel (50 mg/m2), cisplatin (50 mg/m2), and 5-fluorouracil (500 mg/m2) for 5 days. The radiotherapy dose was 1.8-2 Gy per session, up to a total of 50-60 Gy. Results: The complete response (CR) rate was 37.8% in the CF-RT group and 52.6% in the DCF-RT group. Overall survival (OS) rates at 2 and 3 years were 45.0% and 37.5%, respectively, in the CF-RT group and 62.9% and 56.7%, respectively, in the DCF-RT group, with a significant intergroup difference (p = 0.032). Progression-free survival rates at 2 and 3 years were 44.1% and 36.9%, respectively, in the CF-RT group and 45.0% and 45.0%, respectively, in the DCF-RT group (p = 0.10). Local control rates at 2 and 3 years were 59.1% and 54.6%, respectively, in the CF-RT group and 71.8% and 71.8%, respectively, in the DCF-RT group (p = 0.12). The incidence of Grade 3/4 leukopenia was 55.4% (n = 46) in the CF-RT group and 78.9% (n = 30) in the DCF-RT group, with a significant intergroup difference (p = 0.022). The incidence of Grade 3/4 neutropenia was 47.0% (n = 39) in the CF-RT group and 65.8% (n = 25) in the DCF-RT group, with a notable albeit not statistically significant difference between the groups (p = 0.054). There were no significant intergroup differences in anemia, thrombocytopenia, radiation-induced dermatitis, radiation esophagitis, or late adverse events. Conclusions: Rates of OS and CR were improved after treatment with DCF-RT compared with CF-RT. Although DCF-RT-treated patients had higher rates of leukopenia, treatment safety was ensured through proper management of myelotoxicity. DCF-RT is a promising treatment regimen for advanced esophageal cancer.

Concurrent Three Dimensional Conformal Radiotherapy and Chemotherapy with DF Regime in the Treatment for 33 Cases with Advanced Esophageal Carcinoma

Effect of the combination of Elemene and concurrent chemoradiation with cisplatin followed by consolidation chemotherapy with cisplatin and fluorouracil for locally advanced esophageal cancer

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Study of Late Course Three Dimensional-Conformal Radiotherapy Combined with Chemotherapy for 29 Cases with Recurrent Rectal Cancer.

The Effect and Prognosis of Dimen sional Conformal Radiation Therapy for 1348 Cases Esophageal Carcinoma

The Efficacy of Three-Dimensional Conformal Late Course Accelerated Fractionation Radiotherapy for Esophageal Carcinoma

Concurent Chemotherapy Combined with Late Course Accelerated Hyperfractionated Radiotherapy for Advanced Esophageal Carcinoma

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil

Long-Term Outcomes of Three-Dimensional Conformal Radiation Therapy Without Chemotherapy for Esophageal Squamous Cell Carcinoma: A Final Report of a Phase 2 Study

Clinical Study of Concurrent Chemoradiotherapy or Radiotherapy Alone for Esophageal Cancer Patients with Positive Lymph Node Metastasis.

PRELIMINARY OBSERVATION OF 3-DIMENSIONAL CONFORMAL RADIOTHERAPY FOR ESOPHAGEAL CARCINOMA

Comparison of Effects of Three Kinds of Radiation Therapy Methods in the Treatment of Esophageal Carcinoma

Results and Prognostic Factors of 3-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Esophageal Carcinoma

Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma

Clinical Study of Intensity Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Non-surgical Patients with Locally Advanced Esophageal Carcinoma

Dosimetric Comparison Between Conventional and Three Dimensional Conformal Radiation Therapy for Esophageal Carcinoma

Different Radiation Treatment in Esophageal Carcinoma: a Clinical Comparative Study.

Three‐dimensional Conformal Radiation Therapy Alone for Esophageal Squamous Cell Carcinoma: 10‐year Survival Outcomes

High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial